PCORI commits $50 million for COVID-19 research, awards $25 million

PCORI commits $50 million for COVID-19 research, awards $25 million

The Patient-Centered Outcomes Research Institute (PCORI) has announced a $50 million commitment in support of research related to COVID-19 and grants totaling $25 million for other health-related research.

The commitment from the organization will support new and ongoing research on the impacts of COVID-19 on patients, providers, and healthcare systems. Since April, the organization has awarded $17 million to enable researchers to shift the focus of their work to the impacts of COVID-19. Grants for health-related research include $4.2 million to City of Hope, which is exploring strategies designed to improve care for patients recovering from cancer surgery; $3.6 million to the HealthPartners Institute to evaluate the outcomes of two monitoring strategies for insulin-dependent Type 2 diabetic patients; $2.9 million to the University of Kentucky to compare the effectiveness of two online cognitive behavioral therapies in reducing depressive symptoms in people with heart disease; and $1.4 million to the Meharry Medical College to examine whether motivational interviews are effective in improving diabetes-related outcomes among African-American women in the Southeast.

"PCORI continues to marshal its resources to address the unprecedented and constantly evolving challenges created by this pandemic, through innovative funding mechanisms like today‚Äôs enhancements to existing research," said PCORI executive director Nakela L. Cook. "We're also harnessing the power of PCORnet and its network of more than eight hundred thousand clinicians and hundreds of health systems in support of the HERO Registry Program, a national registry of healthcare workers on the front lines of the coronavirus pandemic. Those registered have the option of providing invaluable information about COVID-19 risk factors, medical encounters, and health status that can be used to inform future research projects and enrollment into clinical trials,"  "We also continue our commitment to much needed new research to help answer significant questions regarding treatment and delivery of care that are important to patients and those who care for them."